Perclose believes it's found a major market opportunity by addressing a vexing problem in angioplasty and angiography: management of the catheter access sites. Perclose's biggest challenge may lie simply in getting cardiologists to accept responsibility for a problem that defaults to nursing if they do nothing.
by David Cassak
There's a motto that hangs on the wall at Perclose Inc. , the Menlo Park, CA-based wound closure company:...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
